Jonathan Golledge1, Paul E Norman2, Michael P Murphy3, Ronald L Dalman4. 1. Queensland Research Centre for Peripheral Vascular Disease, College of Medicine and Dentistry, James Cook University, Townsville, Queensland, Australia; Department of Vascular and Endovascular Surgery, The Townsville Hospital, Townsville, Queensland, Australia. Electronic address: jonathan.golledge@jcu.edu.au. 2. School of Surgery, University of Western Australia, Perth, Western Australia, Australia. 3. Division of Vascular Surgery, Indiana University School of Medicine, Indianapolis, Ind. 4. Division of Vascular Surgery, Stanford University School of Medicine, Stanford, Calif.
Abstract
OBJECTIVE: This review describes ongoing efforts to develop a medical therapy to limit abdominal aortic aneurysm (AAA) growth. METHODS: Data from animal model studies, human investigations, and clinical trials are described. RESULTS: Studies in rodent models and human samples have suggested a number of potential targets for slowing or halting AAA growth. A number of clinical trials are now examining the value of medications targeting some of the pathways identified. These trials have a number of challenges, including identifying medications safe to use in older patients with multiple comorbidities, developing accurate outcome assessments, and minimizing the dropout of patients during the trials. Three recent trials have reported no benefit of the antibiotic doxycycline, a mast cell inhibitor, an angiotensin-converting enzyme inhibitor, or a calcium channel blocker in limiting AAA growth. A number of other trials examining angiotensin receptor blockers, cyclosporine, and an antiplatelet agent are currently underway. CONCLUSIONS: Further refinement of drug discovery pathways and testing paradigms are likely needed to develop effective nonsurgical therapies for AAA. Crown
OBJECTIVE: This review describes ongoing efforts to develop a medical therapy to limit abdominal aortic aneurysm (AAA) growth. METHODS: Data from animal model studies, human investigations, and clinical trials are described. RESULTS: Studies in rodent models and human samples have suggested a number of potential targets for slowing or halting AAA growth. A number of clinical trials are now examining the value of medications targeting some of the pathways identified. These trials have a number of challenges, including identifying medications safe to use in older patients with multiple comorbidities, developing accurate outcome assessments, and minimizing the dropout of patients during the trials. Three recent trials have reported no benefit of the antibiotic doxycycline, a mast cell inhibitor, an angiotensin-converting enzyme inhibitor, or a calcium channel blocker in limiting AAA growth. A number of other trials examining angiotensin receptor blockers, cyclosporine, and an antiplatelet agent are currently underway. CONCLUSIONS: Further refinement of drug discovery pathways and testing paradigms are likely needed to develop effective nonsurgical therapies for AAA. Crown
Authors: Nathan K Itoga; Kara A Rothenberg; Paola Suarez; Thuy-Vy Ho; Matthew W Mell; Baohui Xu; Catherine M Curtin; Ronald L Dalman Journal: J Vasc Surg Date: 2018-09-06 Impact factor: 4.268
Authors: Shalin A Parikh; Raymond Gomez; Mirunalini Thirugnanasambandam; Sathyajeeth S Chauhan; Victor De Oliveira; Satish C Muluk; Mark K Eskandari; Ender A Finol Journal: Ann Biomed Eng Date: 2018-08-21 Impact factor: 3.934
Authors: Ying H Shen; Scott A LeMaire; Nancy R Webb; Lisa A Cassis; Alan Daugherty; Hong S Lu Journal: Arterioscler Thromb Vasc Biol Date: 2020-03-25 Impact factor: 8.311
Authors: Corey S Moran; Erik Biros; Smriti M Krishna; Susan K Morton; Daniel J Sexton; Jonathan Golledge Journal: J Am Heart Assoc Date: 2021-02-18 Impact factor: 5.501